These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8520877)

  • 21. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study.
    Goedhals L; Heron JF; Kleisbauer JP; Pagani O; Sessa C
    Ann Oncol; 1998 Jun; 9(6):661-6. PubMed ID: 9681082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
    Campos D; Pereira JR; Reinhardt RR; Carracedo C; Poli S; Vogel C; Martinez-Cedillo J; Erazo A; Wittreich J; Eriksson LO; Carides AD; Gertz BJ
    J Clin Oncol; 2001 Mar; 19(6):1759-67. PubMed ID: 11251007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.
    Hesketh PJ; Gralla RJ; Webb RT; Ueno W; DelPrete S; Bachinsky ME; Dirlam NL; Stack CB; Silberman SL
    J Clin Oncol; 1999 Jan; 17(1):338-43. PubMed ID: 10458252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.
    J Clin Oncol; 1998 Sep; 16(9):2937-42. PubMed ID: 9738561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet.
    Grélot L; Le Stunff H; Milano S; Blower PR; Romain D
    J Pharmacol Exp Ther; 1996 Oct; 279(1):255-61. PubMed ID: 8859001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1992; 28A Suppl 1():S12-6. PubMed ID: 1320913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron.
    Kang YK; Park YH; Ryoo BY; Bang YJ; Cho KS; Shin DB; Kim HC; Lee KH; Park YS; Lee KS; Heo DS; Kim SY; Cho EK; Lim HY; Kim WK; Lee JA; Kim TY; Lee JC; Yoon HJ; Kim NK
    J Int Med Res; 2002; 30(3):220-9. PubMed ID: 12166338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
    Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
    J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An audit of antiemetic use with CMF chemotherapy.
    Brown RS; Brown TK; Hoare D; Gaze MN
    Clin Oncol (R Coll Radiol); 1998; 10(5):313-7. PubMed ID: 9848332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
    Hesketh PJ; Van Belle S; Aapro M; Tattersall FD; Naylor RJ; Hargreaves R; Carides AD; Evans JK; Horgan KJ
    Eur J Cancer; 2003 May; 39(8):1074-80. PubMed ID: 12736106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
    Kubota K; Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T
    Support Care Cancer; 2016 Sep; 24(9):4025-33. PubMed ID: 27129842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.
    Anticancer Drugs; 1999 Jun; 10(5):465-70. PubMed ID: 10477166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
    Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
    Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.